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Dr Gordon Cohen (Seattle, Wash). Thank you for the opportunity
to discuss this important presentation by Dr Nagendran and his col-
leagues at the University of Alberta. This paper was originally to be
discussed by my department chief, Dr Edward Verrier. Unfortu-
nately, Dr Verrier had to depart from the meeting early, so I will
be discussing this paper in his place. Normally I would thank you
for submitting the paper to me well in advance and allowing me
plenty of opportunity to review it and think about it. Having just re-
ceived the paper last night from Dr Verrier puts me in the unusual
position of thanking you on his behalf for allowing him a lot of
time to think about it, but my response to him is, ‘‘Thanks a lot,
Ed, for the advance notice’’ [laughter].
This interesting set of experiments was designed to determine
whether the mitochondrial metabolism of the RV, the LV, and the
pathologically hypertrophied RV are distinct and unique. If so, the
authors believed that they could represent specific targets for en-
hancing RV performance. This work is consistent with other inves-
tigations from this laboratory looking to identify mechanisms that
could be pharmacologically exploited to improve performance in
the struggling or failing RV. I have a few observations and question
for Dr Nagendran.The Journal of ThorFirst, why did you not study LVH as a more clinically relevant or
prevalent problem? If nothing else, why did you not use LVH as
a positive control? If your hypothesis is correct, then you might ex-
pect that an even greater change in mitochondrial membrane poten-
tial would be seen for LVH versus RVH.
Dr Nagendran. Thank you for your comments. The reason for
specifically studying the RV is that most of the therapeutics that
are used on the RV were only established in the LV, and models
of LVH and changes in metabolism that occur in LVH have been
documented. The changes that we show that are unique to other
studies of LVH are the dramatic change in mitochondrial membrane
potential and also coupling it to the changes in glucose oxidation
when treated with DCA, which has already been checked in an
LVH model. What we hope to show by these experiments is that
there are inherently different methods of remodeling in the RV
that may be less adaptive than the LV. To use LVH as a positive
control is a very valid statement. The models for LVH require either
invasive surgery, which would be aortic banding, or use of a sponta-
neously hypertensive rat that developed LVH, both of which intro-
duced significant other variables to our model. That is why we
studied the RV specifically.
Dr Cohen. Thank you for that explanation. Second, it appears
to me that you are studying three different groups of cells, and I
am not sure they all represent the same thing. First, you are look-
ing at human RV muscle in which hypertrophy was documented
by echocardiography. Presumably, this was an increase in RV
wall thickness. In this group of patients, the increase in wall thick-
ness presumably is something that developed slowly over time.
One of the patients was undergoing a transplant, so presumably
that was a long-term process. In the second group you studied
rats. You had PAH induced with monocrotaline and then appar-
ently humanely killed the rats at 2 or 4 weeks after again confirm-
ing an increase in RV wall thickness. Finally, you studied isolated
neonatal rat myocytes that were exposed to phenylephrine for 2
days. Have you done any additional studies to ensure that you
are not studying, for example, cellular edema at 48 hours in neo-
natal myocytes, increase in cell size at 2 weeks, and cellular hyper-
plasia plus or minus increase in cell size in the chronic state? If
not, are you not concerned that you may be studying three differ-
ent cellular states under the heading of RVH?
Dr Nagendran.Your point is well taken. The individual models
of RVH are distinct. That is why in the monocrotaline-induced
model, which is a pathologic model, we wanted to show correlation
to a physiologic model, which is the neonatal model. In regard to
whether these cells are different, when you treat with phenylephrine
and induce hypertrophy, that does not mimic an in vivo–type exper-
iment where you would have true pressure overload though the met-
abolic profile of all three types of hypertrophy were similar. That is
the commonality between them that allows us to umbrella them
under the category of RVH.
Dr Cohen. You looked at NFAT, which increases interleukin 2
activity during organ rejection. It does not appear, though, that you
looked at any other transcription factors to see whether this was an
NFAT-specific response. Was the response specific to NFAT or was
the NFAT response part of some other more complex process that
you observed?
Dr Nagendran. The reason for targeting NFAT specifically is
that NFAT is critically linked to pathologic hypertrophy and cardiacacic and Cardiovascular Surgery c Volume 136, Number 1 177
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ETdevelopment. The reason why we chose to study NFAT is that in our
other studies in cancer and in PAH, we showed a direct link of
NFAT being inhibited by DCA. Once we saw the ex vivo perfusions
and the return of function with DCA treatment, we honed in on sim-
ilar mechanisms that were shown true in other organ systems. That is
why we used NFAT, and indeed phenylephrine’s primary method
of causing hypertrophy in vitro is by an increase in intracellular
calcium, which is the activating step for NFAT by binding to
calcineurin.
Dr Cohen. Finally, how does DCA work in this setting? Is the
DCA causing the mitochondria and the hypertrophied RV to func-
tion better, or is it recruiting more mitochondria? Did you do any
studies to quantify the number of mitochondria present in the hyper-
trophied RV versus the normal RV? Is the change that you see in mi-
tochondrial membrane permeability just a reflection of increased
number of mitochondria that are present? What is the actual poten-
tial clinical utility of DCA? Numerous reports have described the
compound as being neurotoxic.178 The Journal of Thoracic and Cardiovascular Surgery c JulyDrNagendran.With regard to the number of mitochondria, we
are also doing a concurrent study in which we examine the indi-
vidual complexes along the electron transport chain. We remove
the mitochondria from these cells and perform in vitro studies.
There we find that the protein ratio of mitochondrial proteins to
cardiomyocytes is similar in both the control and hypertrophy
hearts. DCA caused hyperpolarized mitochondria to revert to
a more normal depolarized phenotype after 2 days of treatment.
However, in these data alone, we also have evidence that this re-
version is a functional status rather than a change in actual number
of mitochondria. The biogenesis of mitochondria is even more
complex based on the fact that mitochondria undergo fission
when increased energy demands are sensed, as well as undergoing
fusion during times of stress to form rigid networks. Thus the ab-
solute number of mitochondria might not change, while the func-
tional state does.
Dr Cohen. Congratulations on an interesting study and thanks
for the opportunity to discuss the paper.2008
